validation of iwg 2023 criteria for response to treatment with hma in hr-mds
Published 8 months ago • 78 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
5:55
validation of non-invasive ai diagnostic tool for mds
-
4:31
re-evaluating the use of iwg 2006 response criteria in mds
-
3:57
validation of the ipss-m risk stratification system in mds
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
3:35
real-world validation of the value of the ipss-m for prognostication in patients with mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
2:07
ipps-m: incorporating genomic data into the ipps criteria for mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
1:30
the prognostic value of patient-reported outcomes in mds
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
3:32
evaluating response criteria in myelodysplastic syndromes
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
2:22
validation & differences between the ebmt, cibmtr, and gimema early myeloma relapse scores
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
2:48
developing effective methods to study qol in clinical trials in mds